資料載入中.....
|
請使用永久網址來引用或連結此文件:
https://ir.cnu.edu.tw/handle/310902800/34647
|
| 標題: | Recurrent thromboembolism, bleeding, and mortality in Asian patients with venous thromboembolism receiving different oral anticoagulants: A nationwide analysis |
| 作者: | Lee, Mei-Chuan
Liao, Chia-Te
Feng, I-Jung
Yu, Tsung
Chang, Wei-Ting
Shih, Mei-Fen
Su, Hui-Chen
Toh, Han Siong |
| 貢獻者: | Chi Mei Hospital
National Cheng Kung University
Chi Mei Hospital
Southern Taiwan University of Science & Technology
National Sun Yat Sen University
National Cheng Kung University
Southern Taiwan University of Science & Technology
Chia Nan University of Pharmacy & Science
Chi Mei Hospital
Chia Nan University of Pharmacy & Science |
| 關鍵字: | rivaroxaban
risk
population
warfarin
prevention
dabigatran
quality
safety |
| 日期: | 2022 |
| 上傳時間: | 2023-12-11 14:02:32 (UTC+8) |
| 出版者: | LIPPINCOTT WILLIAMS & WILKINS |
| 摘要: | Venous thromboembolism (VTE) is associated with a high risk of morbidity and mortality. However, data on the association between oral anticoagulants and the hazards of VTE complications in Taiwanese patients with VTE is limited. This study aimed to compare the hazards of recurrent VTE, bleeding, and mortality between patients with VTE receiving rivaroxaban, a non-vitamin K antagonist oral anticoagulant (NOAC), and those receiving heparin or low-molecular-weight heparin (LMWH) followed by warfarin. Patients with VTE treated with rivaroxaban, or heparin or LMWH followed by warfarin were enrolled from 2 million random samples from Taiwan's National Health Insurance database between 2013 and 2016. Hazards of recurrent VTE (deep vein thrombosis and pulmonary embolism), major bleeding, and mortality in rivaroxaban and warfarin users were investigated. Survival analyses were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). Users of rivaroxaban (183) and warfarin (456) were included in the study. Patients receiving rivaroxaban did not have significantly lower hazards of developing recurrent VTE (HR, 0.72 [CI, 0.37-1.37], P = .31) and mortality (HR, 0.86 [CI, 0.49-1.50], P = .59) than those receiving heparin or LMWH followed by warfarin. In addition, the hazard ratio of major bleeding was not significantly different between the 2 regimens (HR, 1.80 [CI, 0.39-8.29], P = .45). Rivaroxaban was not associated with lower risks of recurrent VTE and mortality and higher hazards of major bleeding than heparin or LMWH followed by warfarin in Taiwanese patients with VTE. Clinicians may tailor oral anticoagulants for VTE patients according to the patient's characteristics, cost-effectiveness and healthcare system policy. |
| 關聯: | MEDICINE, v.101, n.CB2, pp.CC2, pp.-, |
| 顯示於類別: | [行政單位] 123
|
文件中的檔案:
| 檔案 |
描述 |
大小 | 格式 | 瀏覽次數 |
|---|
| index.html | | 0Kb | HTML | 63 | 檢視/開啟 |
|
在CNU IR中所有的資料項目都受到原著作權保護.
|
